Skip to main content
. 2015 Dec 22;19(5):345–349. doi: 10.5114/wo.2015.56006

Fig. 1.

Fig. 1

Hazard ratios (HR) for patients with NET taking either lanreotide or placebo in the overall population of patients. Subgroups are selected according to primary tumor site, stage of NET and the degree of liver involvement (modified according to [6])